Key result
Colchicine is a first-line adjunct therapy for acute and recurrent pericarditis, with large trials demonstrating significant reductions in recurrences (e.g., 16.7% vs 37.5% in the ICAP trial).
Why the study?
Does colchicine reduce the recurrence of pericarditis and prevent post-pericardiotomy syndrome in patients with pericardial disease or undergoing cardiac surgery?
Does colchicine reduce the recurrence of pericarditis and prevent post-pericardiotomy syndrome in patients with pericardial disease or undergoing cardiac surgery?
This historical review highlights the robust evidence from multiple RCTs supporting colchicine as a first-line adjunct therapy for acute and recurrent pericarditis and for the prevention of post-pericardiotomy syndrome.
No takes yet. Share an insight, caveat, or question.
Supports real-world colchicine use in pericarditis; extends RCT data but leaves open questions for unselected cohorts.
Bayés‐Genís et al. (2017) conducted a review in Pericarditis. Colchicine was evaluated. Colchicine is a first-line adjunct therapy for acute and recurrent pericarditis, with large trials demonstrating significant reductions in recurrences (e.g., 16.7% vs 37.5% in the ICAP trial).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: